<DOC>
	<DOCNO>NCT02487446</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy combination product QVA149 similar efficacy combination product umeclidinium/vilanterol pre-specified endpoint FEV1 AUC0-24h maintain acceptable safety profile .</brief_summary>
	<brief_title>Efficacy Safety Study QVA149 COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male female adult age ≥40 yr Smoking history least 10 pack year Diagnosis stable Chronic Obstructive Pulmonary Disease ( COPD ) classify Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines , 2015 ) Postbronchodilator Forced Expiratory Volume 1 Second ( FEV1 ) &lt; 80 % ≥ 30 % predict normal value postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % Modified Medical Research Council questionnaire grade 2 high Patients respiratory tract infection within 4 week prior Visit 1 Patients concomitant pulmonary disease Patients history asthma Any patient lung cancer history lung cancer Patients history certain cardiovascular comorbid condition Patients known history diagnosis alpha1 antitrypsin deficiency Patients active phase supervise pulmonary rehabilitation program Patients contraindicate inhaled anticholinergic agent β2 agonists Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
</DOC>